Cargando…

Impact of Programmed Death Ligand 1 Expression in Advanced Non-Small–Cell Lung Cancer Patients, Treated by Chemotherapy (GFPC 06-2015 Study)

BACKGROUND: Few data have been published on the clinical and histopathological characteristics of advanced non-small–cell lung cancer (NSCLC) patients with high PD-L1 expression versus intermediate or none and the prognostic value of PD-L1 expression for patients treated with chemotherapy is unknown...

Descripción completa

Detalles Bibliográficos
Autores principales: Auliac, Jean-Bernard, Guisier, Florian, Bizieux, Acya, Assouline, Pascal, Bernardini, Marie, Lamy, Régine, Justeau, Grégoire, François, Geraldine, Damotte, Diane, Chouaïd, Christos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7779294/
https://www.ncbi.nlm.nih.gov/pubmed/33408480
http://dx.doi.org/10.2147/OTT.S288825
_version_ 1783631304455094272
author Auliac, Jean-Bernard
Guisier, Florian
Bizieux, Acya
Assouline, Pascal
Bernardini, Marie
Lamy, Régine
Justeau, Grégoire
François, Geraldine
Damotte, Diane
Chouaïd, Christos
author_facet Auliac, Jean-Bernard
Guisier, Florian
Bizieux, Acya
Assouline, Pascal
Bernardini, Marie
Lamy, Régine
Justeau, Grégoire
François, Geraldine
Damotte, Diane
Chouaïd, Christos
author_sort Auliac, Jean-Bernard
collection PubMed
description BACKGROUND: Few data have been published on the clinical and histopathological characteristics of advanced non-small–cell lung cancer (NSCLC) patients with high PD-L1 expression versus intermediate or none and the prognostic value of PD-L1 expression for patients treated with chemotherapy is unknown. This study was undertaken to prospectively assess the prognostic value of tumor-cell (TC) and immune-cell (IC) PD-L1 expressions for advanced NSCLC patients. METHODS: It was a prospective, multicenter study on advanced NSCLC patients, with performance status 0/1, scheduled, consecutively, to receive first-line platin-based chemotherapy. PD-L1 expression was determined immunochemically (Dako Autostainer and monoclonal antibody 22C3) and its impact on progression-free survival (PFS) and overall survival (OS) assessed. RESULTS: Among 198 patients screened in 19 centers, 140 were included median age: 66.5 ± 10 years; 76.4% men; 79.3% Caucasians; 10.7% nonsmokers; 63.6% adenocarcinomas; <1%, 1–50% and ≥50% TC PD-L1–expression rates were 47.1%, 25.7% and 27.2% of patients, respectively; respective null, intermediate and high rates on ICs were 35.7%, 38.6% and 25.7%. Second- and third-line chemotherapies were administered to 58.6% and 26.4% of the patients, respectively. None received immunotherapy. First-, second- and third-line median (95% CI) PFS lasted 4.6 (3.6–5.2), 3.7 (2.3–4.7) and 2.2 (1.5–4.3) months, respectively; median OS was 16.9 (11.4–19.9) months. No significant PFS and OS differences were observed according to TC or IC PD-L1 expression. CONCLUSION: According to the results of this prospective, multicenter study, neither TC nor IC PD-L1 expression appears to be prognostic for chemotherapy-managed advanced NSCLC patients.
format Online
Article
Text
id pubmed-7779294
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-77792942021-01-05 Impact of Programmed Death Ligand 1 Expression in Advanced Non-Small–Cell Lung Cancer Patients, Treated by Chemotherapy (GFPC 06-2015 Study) Auliac, Jean-Bernard Guisier, Florian Bizieux, Acya Assouline, Pascal Bernardini, Marie Lamy, Régine Justeau, Grégoire François, Geraldine Damotte, Diane Chouaïd, Christos Onco Targets Ther Clinical Trial Report BACKGROUND: Few data have been published on the clinical and histopathological characteristics of advanced non-small–cell lung cancer (NSCLC) patients with high PD-L1 expression versus intermediate or none and the prognostic value of PD-L1 expression for patients treated with chemotherapy is unknown. This study was undertaken to prospectively assess the prognostic value of tumor-cell (TC) and immune-cell (IC) PD-L1 expressions for advanced NSCLC patients. METHODS: It was a prospective, multicenter study on advanced NSCLC patients, with performance status 0/1, scheduled, consecutively, to receive first-line platin-based chemotherapy. PD-L1 expression was determined immunochemically (Dako Autostainer and monoclonal antibody 22C3) and its impact on progression-free survival (PFS) and overall survival (OS) assessed. RESULTS: Among 198 patients screened in 19 centers, 140 were included median age: 66.5 ± 10 years; 76.4% men; 79.3% Caucasians; 10.7% nonsmokers; 63.6% adenocarcinomas; <1%, 1–50% and ≥50% TC PD-L1–expression rates were 47.1%, 25.7% and 27.2% of patients, respectively; respective null, intermediate and high rates on ICs were 35.7%, 38.6% and 25.7%. Second- and third-line chemotherapies were administered to 58.6% and 26.4% of the patients, respectively. None received immunotherapy. First-, second- and third-line median (95% CI) PFS lasted 4.6 (3.6–5.2), 3.7 (2.3–4.7) and 2.2 (1.5–4.3) months, respectively; median OS was 16.9 (11.4–19.9) months. No significant PFS and OS differences were observed according to TC or IC PD-L1 expression. CONCLUSION: According to the results of this prospective, multicenter study, neither TC nor IC PD-L1 expression appears to be prognostic for chemotherapy-managed advanced NSCLC patients. Dove 2020-12-30 /pmc/articles/PMC7779294/ /pubmed/33408480 http://dx.doi.org/10.2147/OTT.S288825 Text en © 2020 Auliac et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Clinical Trial Report
Auliac, Jean-Bernard
Guisier, Florian
Bizieux, Acya
Assouline, Pascal
Bernardini, Marie
Lamy, Régine
Justeau, Grégoire
François, Geraldine
Damotte, Diane
Chouaïd, Christos
Impact of Programmed Death Ligand 1 Expression in Advanced Non-Small–Cell Lung Cancer Patients, Treated by Chemotherapy (GFPC 06-2015 Study)
title Impact of Programmed Death Ligand 1 Expression in Advanced Non-Small–Cell Lung Cancer Patients, Treated by Chemotherapy (GFPC 06-2015 Study)
title_full Impact of Programmed Death Ligand 1 Expression in Advanced Non-Small–Cell Lung Cancer Patients, Treated by Chemotherapy (GFPC 06-2015 Study)
title_fullStr Impact of Programmed Death Ligand 1 Expression in Advanced Non-Small–Cell Lung Cancer Patients, Treated by Chemotherapy (GFPC 06-2015 Study)
title_full_unstemmed Impact of Programmed Death Ligand 1 Expression in Advanced Non-Small–Cell Lung Cancer Patients, Treated by Chemotherapy (GFPC 06-2015 Study)
title_short Impact of Programmed Death Ligand 1 Expression in Advanced Non-Small–Cell Lung Cancer Patients, Treated by Chemotherapy (GFPC 06-2015 Study)
title_sort impact of programmed death ligand 1 expression in advanced non-small–cell lung cancer patients, treated by chemotherapy (gfpc 06-2015 study)
topic Clinical Trial Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7779294/
https://www.ncbi.nlm.nih.gov/pubmed/33408480
http://dx.doi.org/10.2147/OTT.S288825
work_keys_str_mv AT auliacjeanbernard impactofprogrammeddeathligand1expressioninadvancednonsmallcelllungcancerpatientstreatedbychemotherapygfpc062015study
AT guisierflorian impactofprogrammeddeathligand1expressioninadvancednonsmallcelllungcancerpatientstreatedbychemotherapygfpc062015study
AT bizieuxacya impactofprogrammeddeathligand1expressioninadvancednonsmallcelllungcancerpatientstreatedbychemotherapygfpc062015study
AT assoulinepascal impactofprogrammeddeathligand1expressioninadvancednonsmallcelllungcancerpatientstreatedbychemotherapygfpc062015study
AT bernardinimarie impactofprogrammeddeathligand1expressioninadvancednonsmallcelllungcancerpatientstreatedbychemotherapygfpc062015study
AT lamyregine impactofprogrammeddeathligand1expressioninadvancednonsmallcelllungcancerpatientstreatedbychemotherapygfpc062015study
AT justeaugregoire impactofprogrammeddeathligand1expressioninadvancednonsmallcelllungcancerpatientstreatedbychemotherapygfpc062015study
AT francoisgeraldine impactofprogrammeddeathligand1expressioninadvancednonsmallcelllungcancerpatientstreatedbychemotherapygfpc062015study
AT damottediane impactofprogrammeddeathligand1expressioninadvancednonsmallcelllungcancerpatientstreatedbychemotherapygfpc062015study
AT chouaidchristos impactofprogrammeddeathligand1expressioninadvancednonsmallcelllungcancerpatientstreatedbychemotherapygfpc062015study